Literature DB >> 18770995

Screening for colorectal cancer in Italy: 2006 survey.

Manuel Zorzi1, Fabio Falcini, Chiara Fedato, Grazia Grazzini, Priscilla Sassoli de' Bianchi, Carlo Senore, Marcello Vettorazzi, Carmen Visioli, Marco Zappa.   

Abstract

We present the main results of the third survey of the Italian screening programmes for colorectal cancer carried out by the ONS (Osservatorio Nazionale Screening, National Centre for Screening Monitoring) on behalf of the Ministry of Health. During 2006, many new programmes were activated and by the end of the year, 44% of Italians aged 50-69 years were residing in areas covered by organised screening programmes (theoretical extension). Five regions had their entire population covered. In the South of Italy and Islands only one new programme was activated in 2006, with a 10% theoretical extension. The majority of programmes employ the faecal occult blood test (FOBT), while some have adopted the flexible sigmoidoscopy (PS) once in a lifetime, or a combination of both. Overall, about 2,107,000 subjects were invited to undergo FOBT, 70.3% of those to be invited within the year. The adjusted attendance rate was 44.6% and approximately 907,000 subjects were screened. Major differences in the attendance rate were observed among regions, with 10% of programmes reporting values lower than 26%. Positivity rate of FOBT programmes was 5.3% at first and 3.9% at repeat screening: it increased with age and was higher among males than females in all age groups. The average attendance rate to total colonoscopy (TC) was 81% (10th-9Oth percentiles: 64%, 93%). Completion rate of TC was 89%, with higher rates among males. At first screening, the detection rate (DR) per 1,000 screened subjects was 3.1 and 14.6 for invasive cancer and advanced adenomas (AA--adenomas with a diameter > or =1 cm, with villous/tubulo-villous type or with high-grade dysplasia), respectively; the corresponding figures at repeat screening were 1.3 per thousand for cancer and 7.7 per thousand for AA. The DR of cancer and adenomas increased with age and was higher among males; 25% of screen-detected cancers were in TNM stage III+. The positive predictive value (PPV) was 6.8% for cancer and 32.1% for AA at first screening, and 4.0% for cancer and 23.4% for AA at repeat screening. Given the high PPVof a positive FOBT, obtaining a high attendance at TC is therefore crucial. Seven programmes employed PS as the screening test: 51.4% of the target population (about 50,000 subjects) were invited and 7,589 subjects were screened, with an attendance rate of 29.2%. Overall, 88% of FS were classified as complete. TC referral rates ranged between 6.1 and 17.8%, due to different referral criteria. Among subjects referred to colonoscopy, the prevalence of proximal AA and cancer ranged from 6 to 18.2%. The overall DR (subjects with at least one advanced lesion) ranged from 4.9 to 7.5%. In conclusion, during 2006, organised colorectal cancer screening programmes in Italy grew considerably, covering almost half of the eligible population at a national level. Many programmes were activated in the second part of the year, thus their results should be evaluated with caution. However, reported experiences showed good results in terms of attendance and DR, although some critical aspects need to be carefully addressed when planning and implementing screening activity.

Entities:  

Mesh:

Year:  2008        PMID: 18770995

Source DB:  PubMed          Journal:  Epidemiol Prev        ISSN: 1120-9763            Impact factor:   1.901


  8 in total

1.  CT colonography before colonoscopy in subjects with positive faecal occult blood test. Preliminary experience.

Authors:  L Sali; M Falchini; P Della Monica; D Regge; A G Bonanomi; G Castiglione; G Grazzini; M Zappa; F Mungai; C Volpe; M Mascalchi
Journal:  Radiol Med       Date:  2010-07-31       Impact factor: 3.469

2.  The dynamics of colorectal cancer management in 17 countries.

Authors:  Panos Kanavos; Willemien Schurer
Journal:  Eur J Health Econ       Date:  2010-01

3.  Colorectal cancer screening in Europe.

Authors:  Miroslav Zavoral; Stepan Suchanek; Filip Zavada; Ladislav Dusek; Jan Muzik; Bohumil Seifert; Premysl Fric
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

4.  The quality of preventive health care delivered to adults: results from a cross-sectional study in Southern Italy.

Authors:  Benedetto Manuti; Paolo Rizza; Aida Bianco; Carmelo G A Nobile; Maria Pavia
Journal:  BMC Public Health       Date:  2010-06-18       Impact factor: 3.295

5.  Colorectal Cancer Screening in Switzerland: Cross-Sectional Trends (2007-2012) in Socioeconomic Disparities.

Authors:  Stacey A Fedewa; Stéphane Cullati; Christine Bouchardy; Ida Welle; Claudine Burton-Jeangros; Orly Manor; Delphine S Courvoisier; Idris Guessous
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Population screening for colorectal cancer by flexible sigmoidoscopy or CT colonography: study protocol for a multicenter randomized trial.

Authors:  Daniele Regge; Gabriella Iussich; Carlo Senore; Loredana Correale; Cesare Hassan; Alberto Bert; Stefania Montemezzi; Nereo Segnan
Journal:  Trials       Date:  2014-03-28       Impact factor: 2.279

7.  Screening for colorectal cancer with FOBT, virtual colonoscopy and optical colonoscopy: study protocol for a randomized controlled trial in the Florence district (SAVE study).

Authors:  Lapo Sali; Grazia Grazzini; Francesca Carozzi; Guido Castiglione; Massimo Falchini; Beatrice Mallardi; Paola Mantellini; Leonardo Ventura; Daniele Regge; Marco Zappa; Mario Mascalchi; Stefano Milani
Journal:  Trials       Date:  2013-03-15       Impact factor: 2.279

8.  Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?

Authors:  G Grazzini; C B Visioli; M Zorzi; S Ciatto; F Banovich; A G Bonanomi; A Bortoli; G Castiglione; L Cazzola; M Confortini; P Mantellini; T Rubeca; M Zappa
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.